Amgen Inc (NASDAQ:AMGN)

182.43
Delayed Data
As of Feb 21
 -0.55 / -0.30%
Today’s Change
152.16
Today|||52-Week Range
201.23
+4.91%
Year-to-Date
The Zacks Analyst Blog Highlights: Amgen, TOTAL, Marriott, PG&E and Vertex
Feb 21 / Zacks.com - Paid Partner Content
AbbVie Hikes Dividend by 35%, Launches $10B Buyback Plan
Feb 16 / Zacks.com - Paid Partner Content
Top Analyst Report for Amgen, TOTAL S.A. & Marriott
Feb 20 / Zacks.com - Paid Partner Content
Roche's Rituxan Gets Priority Review for Label Expansion
Feb 14 / Zacks.com - Paid Partner Content
Minority Report
Feb 20 / GuruFocus News - Paid Partner Content
Can ImmunoGen's Key Ovarian Cancer Candidate Drive Growth?
Feb 14 / Zacks.com - Paid Partner Content
Novartis Psoriasis Drug Cosentyx Positive in SCALP Study
Feb 20 / Zacks.com - Paid Partner Content
3 ETFs to Watch on Biotech Earnings
Feb 10 / Zacks.com - Paid Partner Content
Roche (RHHBY) to Acquire Flatiron Health for $1.9 Billion
Feb 16 / Zacks.com - Paid Partner Content
Novartis' Cosentyx Label Expanded to Include Scalp Psoriasis
Feb 08 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close182.98
Today’s open183.19
Day’s range182.40 - 185.50
Volume4,054,587
Average volume (3 months)3,250,215
Market cap$131.8B
Data as of 4:15pm ET, 02/21/2018

Growth & Valuation

Earnings growth (last year)-73.73%
Earnings growth (this year)+5.43%
Earnings growth (next 5 years)+4.98%
Revenue growth (last year)+0.45%
P/E ratio67.8
Price/Sales5.61
Price/Book5.24

Competitors

 Today’s
change
Today’s
% change
GILDGilead Sciences----
BIIBBiogen-1.35-0.47%
ILMNIllumina Inc+1.34+0.59%
----
Data as of 4:00pm ET, 02/21/2018

Financials

Next reporting dateApril 24, 2018
EPS forecast (this quarter)$3.20
Annual revenue (last year)$22.8B
Annual profit (last year)$2.0B
Net profit margin8.69%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Robert A. Bradway
Executive Vice President-
Operations
Esteban Santos
Corporate headquarters
Thousand Oaks, California

Forecasts